Skip to Content

'
Bonnie S. Glisson, M.D.

Present Title & Affiliation

Primary Appointment

Professor of Medicine & Internist, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Abell-Hanger Foundation Distinguished Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston
Associate Chair, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Bonnie S. Glisson, MD is a professor at The University of Texas MD Anderson Cancer Center. Dr Glisson graduated from Ohio State University magna cum laude with a BS and an MD. She was a resident at the University of Virginia and a fellow at the University of Florida. She is board certified in internal medicine and medical oncology.

Dr Glisson holds an Ashbel Smith Professorship in the University of Texas System and has received numerous honors and awards for education and mentoring. She has been listed numerous times in the “The Best Doctors in America” and “America’s Top Doctors”. She is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the American Head and Neck Society. Dr Glisson has given numerous lectures and has published dozens of articles and abstracts.

Office Address

The University of Texas MD Anderson Cancer Center
1400 Holcombe Blvd.
John Mendelsohn Faculty Center Building
Unit Number: 432
Houston, TX 77030
Room Number: FC9.2026
Phone: (713) 792-6363
Fax: (713) 792-1220

Education & Training

Degree-Granting Education

1979 Ohio State University, Columbus, OH, MD, Medicine
1976 Ohio State University, Columbus, OH, Graduate School, Graduate School
1975 Ohio State University, Columbus, OH, BS, Magna cum laude, Human Nutrition
1971 Central-Hower High School, Akron, OH, High School Diploma, (Class Valedictorian)

Postgraduate Training

1983-1985 Research Fellowship, Pharmacology and Medical Oncology, University of Florida, Gainesville, FL
1982-1983 Clinical Fellowship, Hematology and Medical Oncology, University of Florida, Gainesville, FL
1979-1982 Clinical Residency, Internal Medicine, University of Virginia, Charlottesville, VA

Experience/Service

Administrative Appointments/Responsibilities

Department Chair ad interim, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2012-4/2013
Deputy Department Chair, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2010-4/2012

Endowed Positions

Ashbel Smith Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center,, Houston, TX, 2006-2012

Selected Publications

Peer-Reviewed Original Research Articles

1. Stewart DJ, Johnson C, Lopez A, Glisson B, Rhee JM, Bekele BN. Extensive disease small cell lung cancer dose-response relationships: Implications for resistance mechanisms. J Thorac Oncol 5(11):1826-34, 11/2010. PMCID: PMC2966343.
2. Glisson BS. Targeting an autocrine loop in small-cell lung cancer: irrelevant target or ineffective drug? Clin Lung Cancer 11(4):222, 7/2010. PMID: 20630822.
3. William WN, Khuri FR, Fossella FV, Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman SM, Kim ES. Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer as Frontline and Second-Line Therapy. Am J Clin Oncol 33(2):148-52, 4/2010. e-Pub 8/2009. PMID: 19687727.
4. Frank SJ, Rosenthal DI, Petsuksiri J, Ang KK, Morrison WH, Weber RS, Glisson BS, Chao KS, Schwartz DL, Chronowski GM, El-Naggar AK, Garden AS. Intensity-Modulated Radiotherapy for Cervical Node Squamous Cell Carcinoma Metastases from Unknown Head-and-Neck Primary Site: M. D. Anderson Cancer Center Outcomes and Patterns of Failure. Int J Radiat Oncol Biol Phys. e-Pub 3/2010. PMID: 20207504.
5. Kies MS, Holsinger FC, Lee JJ, William WN, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers L, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V. Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial. J Clin Oncol 28(1):8-14, 1/2010. e-Pub 11/2009. PMCID: PMC2799235.
6. Johnson FM, Glisson BS. Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC? Nat Rev Clin Oncol 6(10):562-3, 10/2009. PMID: 19786998.
7. Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, Jones C, Ang KK. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. Journal of Clinical Oncology 27:3684-3690, 8/2009.
8. Saigal B, Glisson BS, Johnson FM. Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma. Anticancer Drugs 19(5):465-75, 6/2008. PMID: 18418213.
9. Thariat J, Ahamad A, El-Naggar AK, Williams MD, Holsinger FC, Glisson BS, Allen PK, Morrison WH, Weber RS, Ang KK, Garden AS. Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study. Cancer 112(12):2698-709, 6/2008. e-Pub 4/2008. PMID: 18429002.
10. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 24(25):4163-9, 9/2006. PMID: 16943532.
11. Raju U, Riesterer O, Torres M, Molkentine D, Pickett J, Koto Massashi, Matsumoto F, Johnson FM, Glisson B, Milas L, Ang KK. Mechanisms of radiation sensitization by inhibition of c-Src/c-Abl signaling. Cancer. Submitted.

Grant & Contract Support

Title: Phase I/II Open Label Dose Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of SC16LD6.5 as a Single Agent in Patients with Recurrent Small Cell Lung Cancer
Funding Source: Stemcentrx, Inc
Role: Principal Investigator
Duration: 11/18/2013 - 11/17/2016
 
Title: Tryhard: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (TYKERB) for Non-HPv Locally Advanced Head and Neck Cancer with Concurrent Chemoradiation
Funding Source: Foundation NIH
Role: Co-Principal Investigator
Principal Investigator: G. Brandon Gunn, MD
Duration: 6/18/2013 - 6/17/2016
 
Title: Lung Cancer Mutation Consortium (LCMC)
Funding Source: University of Colorado Cancer Center
Role: Co-Principal Investigator
Principal Investigator: Paul Bunn, MD
Duration: 8/1/2012 - 7/31/2014
 
Title: Chemo-Immunotherapy for Relapsed or Refractory Nasopharyngeal Carcinoma
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Collaborator
Principal Investigator: Dr. Chrystal Louis
Duration: 12/1/2011 - 5/31/2014

Last updated: 6/12/2014